Insight

Sumanta K. Pal: Terrific AUC3 debate between Michiel van der Heijden and Roger Li on NMIBC management

Sumanta K. Pal/X

Jan 26, 2025, 08:41

Sumanta K. Pal: Terrific AUC3 debate between Michiel van der Heijden and Roger Li on NMIBC management

Sumanta K. Pal, Medical Oncologist at City of Hope, posted the following on X:

“Terrific AUC3 debate between Michiel van der Heijden and Roger Li on NMIBC management (local v systemic). As both concede, data for emerging local therapies very compelling, but possibly (possibly) a role for local + systemic.

Great paper from Roger in Nature Medicine that supports this approach.”

sumanta k. pal

Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial

Authors: Roger Li et al.

Sumanta K. Pal: Terrific AUC3 debate between Michiel van der Heijden and Roger Li on NMIBC management

Alexander R. A. Anderson Carlos M Moran Segura Colin P.N. Dinney Denise Dorman G. Daniel Grass Gustavo Borjas James J. Mulé James M. Burke Jasreman Dhillon Jingsong Zhang John J. Powers Jose R. Conejo-Garcia Joseph O. Johnson Julio M. Pow-Sang Logan Zemp Michael A. Poch Michiel van der Heijden Nancy Y. Villa Natasha Francis Paulo C. Rodriguez Philippe E. Spiess Roger Li Rohit K. Jain Scott M. Gilbert Tingyi Li Wade J. Sexton Xiaoqing Yu Xuefeng Wang Youngchul Kim

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Writer?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...